{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T08:17:54Z","timestamp":1787818674886,"version":"build-2784847793"},"reference-count":34,"publisher":"American Association for Cancer Research (AACR)","issue":"8","license":[{"start":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T00:00:00Z","timestamp":1787788800000},"content-version":"vor","delay-in-days":26,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100019827","name":"Atrium Health Foundation","doi-asserted-by":"publisher","award":["P30CA012197"],"award-info":[{"award-number":["P30CA012197"]}],"id":[{"id":"10.13039\/501100019827","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["aacrjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,8,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title\/>\n                    <jats:p>Pathologic complete response (pCR) after cisplatin-based neoadjuvant chemotherapy (NAC) is associated with improved outcomes in muscle-invasive bladder cancer (MIBC), but genomic predictors of benefit remain unvalidated. Based on observations in lung cancer, we hypothesized that patients with MIBC with high tumor mutational burden (TMB) would be unlikely to benefit from NAC, indicated by residual disease after cystectomy. Pretreatment tumor specimens from patients treated with cisplatin-based NAC were analyzed using Tempus xT\/xR platforms. Sample size was prespecified by statistical design. High TMB was defined as the upper TMB quintile within the cohort. Correlation of TMB values and genomic variants with outcomes was performed using logistic regression, Cox proportional hazards models, and Kaplan\u2013Meier techniques. Ninety-one patients were included, with a median follow-up of 63.6 months. pCR occurred in 31.9%. Median TMB was 8.9 mutations per megabase (Mut\/Mb). Contrary to the prespecified hypothesis, higher TMB was associated with more favorable outcomes. Patients in the upper TMB quintile had a numerically higher pCR rate (47.4% vs. 27.8%; P = 0.165) and improved relapse-free survival (RFS)\/overall survival [OS; hazard ratio (HR), 0.456; P = 0.08 and HR, 0.495; P = 0.16]. Using a clinically relevant cutoff, TMB \u2265 10 Mut\/Mb was associated with higher pCR [43.6% vs. 23.1%; odds ratio (OR), 0.39; P = 0.044] and improved RFS (HR, 0.330; P &amp;lt; 0.001) and OS (HR, 0.388; P = 0.013). Exploratory analyses showed a trend toward enrichment of mismatch repair alterations (OR, 3.57; P = 0.087) in TMB-high tumors. Baseline TMB \u2265 10 Mut\/Mb was associated with improved pathologic response and survival in MIBC treated with cisplatin-based NAC and warrants prospective evaluation in contemporary perioperative regimens.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Significance:<\/jats:title>\n                    <jats:p>In MIBC treated with cisplatin-based neoadjuvant chemotherapy, we found that baseline TMB \u226510 Mut\/Mb was associated with higher pCR rates and improved RFS and OS. These findings support the prospective study of TMB as a prognostic biomarker in contemporary perioperative treatment regimens.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1158\/2767-9764.crc-26-0255","type":"journal-article","created":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T19:51:37Z","timestamp":1786650697000},"page":"2010-2016","update-policy":"https:\/\/doi.org\/10.1158\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Tumor Mutational Burden and Clinical Outcomes in Patients with Muscle-Invasive Bladder Cancer Treated with Neoadjuvant Chemotherapy"],"prefix":"10.1158","volume":"6","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4293-4680","authenticated-orcid":false,"given":"Earle F.","family":"Burgess","sequence":"first","affiliation":[{"name":"1Atrium Health Wake Forest Baptist Comprehensive Cancer Center, Charlotte, North Carolina."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5231-4859","authenticated-orcid":false,"given":"Landon C.","family":"Brown","sequence":"additional","affiliation":[{"name":"1Atrium Health Wake Forest Baptist Comprehensive Cancer Center, Charlotte, North Carolina."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6330-6945","authenticated-orcid":false,"given":"Michael","family":"McCormack","sequence":"additional","affiliation":[{"name":"2Atrium Health Wake Forest Baptist Comprehensive Cancer Center, Winston-Salem, North Carolina."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8630-7430","authenticated-orcid":false,"given":"Liang","family":"Liu","sequence":"additional","affiliation":[{"name":"2Atrium Health Wake Forest Baptist Comprehensive Cancer Center, Winston-Salem, North Carolina."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7323-7637","authenticated-orcid":false,"given":"Nury","family":"Steuerwald","sequence":"additional","affiliation":[{"name":"1Atrium Health Wake Forest Baptist Comprehensive Cancer Center, Charlotte, North Carolina."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2121-7543","authenticated-orcid":false,"given":"Ericson","family":"Stoen","sequence":"additional","affiliation":[{"name":"2Atrium Health Wake Forest Baptist Comprehensive Cancer Center, Winston-Salem, North Carolina."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5382-0481","authenticated-orcid":false,"given":"Metamia","family":"Ciampricotti","sequence":"additional","affiliation":[{"name":"3Tempus AI, Inc., Chicago, Illinois."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5457-5323","authenticated-orcid":false,"given":"Patrick M.","family":"Doherty","sequence":"additional","affiliation":[{"name":"3Tempus AI, Inc., Chicago, Illinois."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-0812-4116","authenticated-orcid":false,"given":"Edward","family":"Williams","sequence":"additional","affiliation":[{"name":"3Tempus AI, Inc., Chicago, Illinois."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8006-7015","authenticated-orcid":false,"given":"Peter E.","family":"Clark","sequence":"additional","affiliation":[{"name":"1Atrium Health Wake Forest Baptist Comprehensive Cancer Center, Charlotte, North Carolina."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2235-1851","authenticated-orcid":false,"given":"Wei","family":"Zhang","sequence":"additional","affiliation":[{"name":"2Atrium Health Wake Forest Baptist Comprehensive Cancer Center, Winston-Salem, North Carolina."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2495-8822","authenticated-orcid":false,"given":"James T.","family":"Symanowski","sequence":"additional","affiliation":[{"name":"1Atrium Health Wake Forest Baptist Comprehensive Cancer Center, Charlotte, North Carolina."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1086","published-online":{"date-parts":[[2026,8,27]]},"reference":[{"key":"2026082703284940300_bib1","doi-asserted-by":"publisher","first-page":"2102","DOI":"10.1056\/NEJMoa2034442","article-title":"Adjuvant nivolumab versus placebo in muscle-invasive urothelial carcinoma","volume":"384","author":"Bajorin","year":"2021","journal-title":"N Engl J Med"},{"key":"2026082703284940300_bib2","doi-asserted-by":"publisher","first-page":"1773","DOI":"10.1056\/NEJMoa2408154","article-title":"Perioperative durvalumab with neoadjuvant chemotherapy in operable bladder cancer","volume":"391","author":"Powles","year":"2024","journal-title":"N Engl J Med"},{"key":"2026082703284940300_bib3","doi-asserted-by":"publisher","first-page":"1927","DOI":"10.1016\/s0140-6736(03)13580-5","article-title":"Neoadjuvant chemotherapy in invasive bladder cancer: a systematic review and meta-analysis","volume":"361","author":"Advanced Bladder Cancer Meta-analysis Collaboration","year":"2003","journal-title":"Lancet"},{"key":"2026082703284940300_bib4","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1056\/NEJMoa022148","article-title":"Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer","volume":"349","author":"Grossman","year":"2003","journal-title":"N Engl J Med"},{"key":"2026082703284940300_bib5","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1016\/j.eururo.2015.01.014","article-title":"ERBB2 mutations characterize a subgroup of muscle-invasive bladder cancers with excellent response to neoadjuvant chemotherapy","volume":"69","author":"Groenendijk","year":"2016","journal-title":"Eur Urol"},{"key":"2026082703284940300_bib6","doi-asserted-by":"publisher","first-page":"959","DOI":"10.1016\/j.eururo.2015.07.009","article-title":"Defects in DNA repair genes predict response to neoadjuvant cisplatin-based chemotherapy in muscle-invasive bladder cancer","volume":"68","author":"Plimack","year":"2015","journal-title":"Eur Urol"},{"key":"2026082703284940300_bib7","doi-asserted-by":"publisher","first-page":"1140","DOI":"10.1158\/2159-8290.CD-14-0623","article-title":"Somatic ERCC2 mutations correlate with cisplatin sensitivity in muscle-invasive urothelial carcinoma","volume":"4","author":"Van Allen","year":"2014","journal-title":"Cancer Discov"},{"key":"2026082703284940300_bib8","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1016\/j.eururo.2022.07.023","article-title":"Assessment of predictive genomic biomarkers for response to cisplatin-based neoadjuvant chemotherapy in bladder cancer","volume":"83","author":"Gil-Jimenez","year":"2023","journal-title":"Eur Urol"},{"key":"2026082703284940300_bib9","doi-asserted-by":"publisher","first-page":"2916","DOI":"10.1158\/1078-0432.CCR-14-1213","article-title":"Intratumoral heterogeneity: from diversity comes resistance","volume":"21","author":"Pribluda","year":"2015","journal-title":"Clin Cancer Res"},{"key":"2026082703284940300_bib10","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1016\/j.ccell.2020.03.007","article-title":"Intratumor heterogeneity: the Rosetta stone of therapy resistance","volume":"37","author":"Marusyk","year":"2020","journal-title":"Cancer Cell"},{"key":"2026082703284940300_bib11","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1126\/science.1227670","article-title":"Variable clonal repopulation dynamics influence chemotherapy response in colorectal cancer","volume":"339","author":"Kreso","year":"2013","journal-title":"Science"},{"key":"2026082703284940300_bib12","doi-asserted-by":"publisher","first-page":"888951","DOI":"10.3389\/fonc.2022.888951","article-title":"Mutant-allele tumor heterogeneity, a favorable biomarker to assess intra-tumor heterogeneity, in advanced lung adenocarcinoma","volume":"12","author":"Wu","year":"2022","journal-title":"Front Oncol"},{"key":"2026082703284940300_bib13","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1186\/s40425-019-0581-5","article-title":"The correlations of tumor mutational burden among single-region tissue, multi-region tissues and blood in non-small cell lung cancer","volume":"7","author":"Zhang","year":"2019","journal-title":"J Immunother Cancer"},{"key":"2026082703284940300_bib14","doi-asserted-by":"publisher","first-page":"1353","DOI":"10.1016\/S1470-2045(20)30445-9","article-title":"Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study","volume":"21","author":"Marabelle","year":"2020","journal-title":"Lancet Oncol"},{"key":"2026082703284940300_bib15","doi-asserted-by":"publisher","first-page":"2193","DOI":"10.1038\/s41467-017-02320-7","article-title":"Mutational patterns in chemotherapy resistant muscle-invasive bladder cancer","volume":"8","author":"Liu","year":"2017","journal-title":"Nat Commun"},{"key":"2026082703284940300_bib16","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1186\/s13046-019-1192-1","article-title":"PD-L1 expression and tumor mutational burden status for prediction of response to chemotherapy and targeted therapy in non-small cell lung cancer","volume":"38","author":"Chen","year":"2019","journal-title":"J Exp Clin Cancer Res"},{"key":"2026082703284940300_bib17","doi-asserted-by":"publisher","first-page":"480","DOI":"10.3389\/fonc.2020.00480","article-title":"Tumor mutation burden correlates with efficacy of chemotherapy\/targeted therapy in advanced non-small cell lung cancer","volume":"10","author":"Lin","year":"2020","journal-title":"Front Oncol"},{"key":"2026082703284940300_bib18","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1186\/s13000-023-01401-0","article-title":"DNA damage response and repair gene mutations are associated with tumor mutational burden and outcomes to platinum-based chemotherapy\/immunotherapy in advanced NSCLC patients","volume":"18","author":"Gu","year":"2023","journal-title":"Diagn Pathol"},{"key":"2026082703284940300_bib19","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1007\/s12094-022-02924-6","article-title":"Tumor mutational burden and efficacy of chemotherapy in lung cancer","volume":"25","author":"Song","year":"2023","journal-title":"Clin Transl Oncol"},{"key":"2026082703284940300_bib20","doi-asserted-by":"publisher","first-page":"1351","DOI":"10.1038\/s41587-019-0259-z","article-title":"Integrated genomic profiling expands clinical options for patients with cancer","volume":"37","author":"Beaubier","year":"2019","journal-title":"Nat Biotechnol"},{"key":"2026082703284940300_bib21","doi-asserted-by":"publisher","first-page":"2384","DOI":"10.18632\/oncotarget.26797","article-title":"Clinical validation of the tempus xT next-generation targeted oncology sequencing assay","volume":"10","author":"Beaubier","year":"2019","journal-title":"Oncotarget"},{"key":"2026082703284940300_bib22","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1007\/s40291-023-00650-5","article-title":"Validation of a transcriptome-based assay for classifying cancers of unknown primary origin","volume":"27","author":"Michuda","year":"2023","journal-title":"Mol Diagn Ther"},{"key":"2026082703284940300_bib23","volume-title":"Tempus xR validation summary","author":"Tempus AI, Inc","year":"2023"},{"key":"2026082703284940300_bib24","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1186\/s13073-017-0424-2","article-title":"Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden","volume":"9","author":"Chalmers","year":"2017","journal-title":"Genome Med"},{"key":"2026082703284940300_bib25","doi-asserted-by":"publisher","first-page":"5353","DOI":"10.1158\/1078-0432.CCR-23-3518","article-title":"Association of tumor mutational burden and PD-L1 with the efficacy of pembrolizumab with or without chemotherapy versus chemotherapy in advanced urothelial carcinoma","volume":"30","author":"Fl\u00e9chon","year":"2024","journal-title":"Clin Cancer Res"},{"key":"2026082703284940300_bib26","doi-asserted-by":"publisher","first-page":"1257","DOI":"10.1056\/NEJMoa2511674","article-title":"Perioperative enfortumab vedotin and pembrolizumab in bladder cancer","volume":"394","author":"Vulsteke","year":"2026","journal-title":"N Engl J Med"},{"key":"2026082703284940300_bib27","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1016\/j.euo.2024.12.006","article-title":"Genomic biomarkers associated with enfortumab vedotin outcomes for patients with advanced urothelial carcinoma: analysis of UNITE study data","volume":"8","author":"Jindal","year":"2025","journal-title":"Eur Urol Oncol"},{"key":"2026082703284940300_bib28","doi-asserted-by":"publisher","first-page":"1808","DOI":"10.1158\/2159-8290.CD-20-0522","article-title":"Tumor mutational burden as a predictive biomarker in solid tumors","volume":"10","author":"Sha","year":"2020","journal-title":"Cancer Discov"},{"key":"2026082703284940300_bib29","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1038\/cdd.2013.67","article-title":"Immune-based mechanisms of cytotoxic chemotherapy: implications for the design of novel and rationale-based combined treatments against cancer","volume":"21","author":"Bracci","year":"2014","journal-title":"Cell Death Differ"},{"key":"2026082703284940300_bib30","doi-asserted-by":"publisher","first-page":"4858","DOI":"10.1038\/s41467-020-18640-0","article-title":"Molecular correlates of cisplatin-based chemotherapy response in muscle invasive bladder cancer by integrated multi-omics analysis","volume":"11","author":"Taber","year":"2020","journal-title":"Nat Commun"},{"key":"2026082703284940300_bib31","doi-asserted-by":"publisher","first-page":"90","DOI":"10.3389\/fimmu.2019.00090","article-title":"The role of glycosphingolipids in immune cell functions","volume":"10","author":"Zhang","year":"2019","journal-title":"Front Immunol"},{"key":"2026082703284940300_bib32","doi-asserted-by":"publisher","first-page":"6970","DOI":"10.1038\/s41467-024-51495-3","article-title":"Inhibition of glycosphingolipid synthesis with eliglustat in combination with immune checkpoint inhibitors in advanced cancers: preclinical evidence and phase I clinical trial","volume":"15","author":"Dong","year":"2024","journal-title":"Nat Commun"},{"key":"2026082703284940300_bib33","doi-asserted-by":"publisher","first-page":"678896","DOI":"10.3389\/fonc.2021.678896","article-title":"Curative effect and survival assessment comparing gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin and cisplatin as neoadjuvant therapy for bladder cancer: a systematic review and meta-analysis","volume":"11","author":"Wu","year":"2021","journal-title":"Front Oncol"},{"key":"2026082703284940300_bib34","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1016\/S1470-2045(23)00587-9","article-title":"Perioperative dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin in muscle-invasive bladder cancer (VESPER): survival endpoints at 5 years in an open-label, randomised, phase 3 study","volume":"25","author":"Pfister","year":"2024","journal-title":"Lancet Oncol"}],"container-title":["Cancer Research Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/aacrjournals.org\/cancerrescommun\/article-pdf\/doi\/10.1158\/2767-9764.CRC-26-0255\/3821148\/crc-26-0255.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/cancerrescommun\/article-pdf\/6\/8\/2010\/3825489\/crc-26-0255.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/cancerrescommun\/article-pdf\/6\/8\/2010\/3825489\/crc-26-0255.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T07:28:52Z","timestamp":1787815732000},"score":1,"resource":{"primary":{"URL":"https:\/\/aacrjournals.org\/cancerrescommun\/article\/6\/8\/2010\/787714\/Tumor-Mutational-Burden-and-Clinical-Outcomes-in"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,1]]},"references-count":34,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026,8,1]]}},"URL":"https:\/\/doi.org\/10.1158\/2767-9764.crc-26-0255","relation":{"is-supplemented-by":[{"id-type":"doi","id":"10.1158\/2767-9764.33349419","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.33349413","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.33349434","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.33349422","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.33349428","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.33349416","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.33349437","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.33349425","asserted-by":"object"}],"has-preprint":[{"id-type":"doi","id":"10.1158\/2767-9764.c.8677479","asserted-by":"object"}]},"ISSN":["2767-9764"],"issn-type":[{"value":"2767-9764","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,1]]}}}